Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer

Urology

Volumn 48, Issue 6, 1996, Pages 957-962

  Stricker, Phillip ^a,b   Pryor, Kimberley ^a   Nicholson, Timothy ^a   Goldstein, David ^a   Golovsky, David ^a   Ferguson, Richard ^a   Nash, Peter ^a   Ehsman, Stuart ^a   Rumma, Juri ^a   Mammen, George ^a   Penny, Ronald ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BCG VACCINE; CHLORIDE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; RECOMBINANT ALPHA2B INTERFERON; THIOTEPA; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER IRRIGATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; URINARY TRACT INFECTION; BLADDER TUMOR; FOLLOW UP; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; MALE; URINARY BLADDER NEOPLASMS;

EID: 0030333085     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00375-5     Document Type: Article

References (21)

1. 1. Wingo PE, Tong T, and Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45: 8-30, 1995.
2. 2. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573-580, 1992.
3. 3. Vegt PDJ, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, and van der Meijden AP: A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 153: 929-933, 1995.
4. 4. Lamm DL: Carcinoma in situ. Urol Clin North Am 19: 499-508, 1992.
5. 5. Morales A, Eidinger D, and Bruce AW: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976.
6. 6. Lamm DL: BCG therapy of papillary tumours: a review of worldwide Phase III trials, in Pagano F, and Bassi P (Eds): BCG Immunotherapy in Bladder Cancer. Padova, Cooperativa Libraria Editrice Universita di Padova, 1994, pp 33-43.
7. 7. Herr HW, Wartinger DD, Fair WR, and Oettgen HF: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147: 1020-1023, 1992.
8. 8. Lamm DL: Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 19: 565-572, 1992.
9. 9. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, and Garbeglio A: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 146: 32-35, 1991.
10. 10. Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J, et al: Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 6: 476-483, 1988.
11. 11. Glashan RW: A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144: 658-661, 1990.
12. 12. Williams RD: Intravesical interferon alfa in the treatment of superficial bladder cancer. Semin Oncol 15: 10-13, 1988.
13. 13. Lamm DL: BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol 27 (suppl 1 ): 2-8, 1995.
14. 14. Pryor K, Russell P, Stricker P, Golovsky D, and Penny R: Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells. Cancer Immunol Immunother 41: 309-316, 1995.
15. 15. Martinez-Pineiro JA, Solsona E, Flores N, and Isorna S: Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur Urol 27 (suppl 1): 13, 1995.
16. 16. Sarosdy M, et al. High-dose versus low-dose intravesical interferon-alpha 2b in the treatment of carcinoma in situ: a randomized controlled study. Anticancer Drugs 3: 13-17, 1992.
17. 17. Nadler RB, Catalona WJ, Hudson MA, and Ratliff TL: Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 152: 367-373, 1994.
18. 18. Morales A: Improvements in the use of BCG for superficial bladder cancer (abstract 553). J Urol 139: 301A, 1988.
19. 19. Pagano F, Bassi P, Piazza N, Abatangelo G, Drago, Ferrante GL, and Milani C: Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 27 (suppl 1): 19-22, 1995.
20. 20. Mack D, and Frick J: Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in highrisk superficial bladder cancer. Urology 45: 958-961, 1995.
21. 21. Hoeltl W, Hasun R, and Albrecht W: Prospective, randomized trial to evaluate high-versus low-dose interferon-alpha 2b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder. Anticancer Drugs 3: 29-32, 1992.